

ASSOCIATION OF BREAST SURGERY CONFERENCE

ABS
ASSOCIATION OF
BREAST SURGERY

18th & 19th June 2018, ICC Birmingham



CONFERENCE PROGRAMME

www.associationofbreastsurgery.org.uk

HC21

Healthcare

Keller Funnel 2

ARTIA

Natrelle

REVOLVE[™]
Advanced Adipose System

Plastic and Reconstructive Surgery
Complete Breast Surgery Portfolio

Stand 24 & Stand 30

Reduction of post-op
wound complications^{1,5,6}
This changes everything.

The use of PICO as part of a treatment protocol resulted in a reduction of post-operative complications associated with a closed surgical incision, in high risk patient groups.²⁻⁴ For patients at risk, this changes everything.

Helping you get CLOSER TO ZERO[®] surgical site complications.
www.smith-nephew.com/pico

 smith&nephew

PICO[°] 7

Single Use Negative Pressure
Wound Therapy System



Supporting healthcare professionals

References 1. Pellino et al., Effects of a new pocket device for negative pressure wound therapy on surgical wounds of patients affected with Crohn's disease. *Apicaltrial: Surgical Innovation* Jul 2014;21(2):204-212. 2. Salvaggi et al., New Advances in Negative Pressure Wound Therapy (NPWT) for Surgical Wounds of Patients Affected with Crohn's Disease. *Surg Technol Int*. 2014;24:83-89. 3. Bulough et al., Changing woundcare protocols to reduce post-operative caesarean section infection and readmission. *Wounds UK* 2014; Vol10, No1, 72-76. 4. Bulough et al., Reducing C-section wound complications. *Clin Serv J* 2015; (April): 2-6. 5. Pellino et al., Preventive NPWT over closed incisions in general surgery. *Doveajournal International Journal of Surgery* 2014;12 Suppl 2:564-8. 6. Gallano R, et al., The effects of a single use canister-free Negative Pressure Wound Therapy (NPWT) System[®] on the prevention of postsurgical wound complications in patients undergoing bilateral breast reduction surgery. Presented at the 30th Annual Scientific Meeting of the British Association of Aesthetic Plastic Surgeons, London 25/26 September 2014. [®]Trademark of Smith & Nephew | All Trademarks acknowledged | ©April 2018 Smith & Nephew 11875.



President's Welcome

Welcome to the 2018 ABS Conference. The first dedicated breast surgery conferences in the UK were the meetings held at the National Motorcycle Museum just outside Birmingham in the late 1990s and 2000s. Breast surgeons and nurses would travel from all over the UK to attend those memorable one day meetings where the annual screening audit data would be debated. After a 10 year gap we return to our 'spiritual home', but now giving delegates the opportunity to stay overnight, to 'network' at the ABS Dinner and enjoy the modern city of Birmingham. The International Conference Centre is a fantastic venue providing great facilities for the ever expanding needs of our annual conference.

This is Katy Hogben's last event after five years as our Meetings Secretary and once again she has coordinated a varied programme with something for everyone. We have a fantastic array of international guests invited to speak on a diverse range of topics such as Diptendra Sarkar sharing his extensive experience of managing locally advanced breast cancer in Kolkata, India; Giuseppe Catanuto from Catania, Italy speaking on both de-escalation of oncoplastic breast surgery and breast morphology; Walter Weber from Basel describing breast surgical training in Switzerland and standardisation of oncoplastic breast conserving surgery; and Henry Kuerer from Houston, USA also giving us his views on de-escalating breast cancer surgery as well as providing a cautionary note for us all when discussing stress and burnout in medical professionals.

Following last year's successful collaboration we are once again delighted to welcome members of the Society of Irish Breast Surgeons and thank them for organising a session on young women with breast cancer. The number and quality of abstracts submitted for the meeting continues to increase and I am sure there will be hot competition in the oral and poster prize sessions. Please take the opportunity to visit the trade exhibition throughout the two days as the ABS meeting could not succeed without the generosity of our sponsors.

I hope that you will be spoilt for choice when deciding which sessions to attend. The sessions vary from very surgical topics such as implant reconstruction to more general themes such as clinical leadership. They cover the breadth of breast multidisciplinary management from genetic testing to living with and beyond breast cancer. Breast surgery has been in the headlines for the wrong reasons over the last year and it is also right that we reflect on the lessons learnt from the Paterson case.

I hope your time in Birmingham is educational, productive and above all enjoyable.

A handwritten signature in blue ink, which appears to read 'D. Mark Sibbering'.

Mark Sibbering
ABS President

ABS Conference • 18th & 19th June 2018, ICC Birmingham

Monday 18th June 2018 – At a glance

	Hall 1	Hall 5	Hall 8
09:00 to 10:30	Session 1: Post Paterson: Lessons learnt	Session 2: Mammary Fold Session	Session 3: Nursing Hot Topics
10:30 to 11:00	Tea and Coffee Break (Hall 3)		
11:00 to 12:30	Session 4: Implant reconstruction infection and loss rates – time to act	Session 5: Prize Papers	
12:30 to 14:00	Lunch Break (Hall 3)		
12:40 to 13:40		Educational Symposium <i>Sponsored by Pfizer</i> Advances in the management of ER positive HER2 negative breast cancer	
13:05 to 13:50			ABS Nurse Members' Meeting
13:15 to 13:45	Poster Prize Session (Balcony, Hall 3)		
14:00 to 14:30	Session 6: Invited Lecture		
14:35 to 16:05	Session 7: Oncoplastics & Aesthetic Session	Session 8: SIBS Session: Breast Cancer in Young Women	Session 9: Submitted Papers
16:05 to 16:35	Tea and Coffee Break (Hall 3)		
16:35 to 18:05	Session 10: Clinical Practice & Standards Session	Session 11: Hot Topics I	Session 12: Living with and beyond breast cancer – taking the strategy forward
18:05 to 19:15	Poster viewing & drinks reception (Hall 3)		
18:15 to 18:45			ABS AGM – open to ABS members only

Session 1

09:00 to 10:30	Hall 1
	Post Paterson: Lessons learnt <i>Chairs: Mrs Katy Hogben and Mr Mark Sibbering</i>
09:00 to 09:05	Introduction <i>Mr Mark Sibbering, Royal Derby Hospital</i>
09:05 to 09:45	The Paterson Case <i>Prof Philip Drew, Royal Cornwall Hospital Trust, Truro</i> <i>Prof Gordon Wishart, Anglia Ruskin University School of Medicine</i> <i>Mr Steven Thrush, Worcestershire Royal Hospital</i>
09:45 to 09:55	ABS Action Plan <i>Mr Mark Sibbering, Royal Derby Hospital</i>
09:55 to 10:05	Bullying and undermining in the workplace <i>Miss Leena Chagla, St Helen's Hospital</i>
10:05 to 10:15	ABS Clinical Guidance <i>Mr Ashu Gandhi, University of South Manchester NHS Foundation Trust</i>
10:15 to 10:25	Multidisciplinary Team Working <i>Mr Mark Sibbering, Royal Derby Hospital</i>
10:25 to 10:30	NHS BSP Incident Update <i>Mr Mark Sibbering, Royal Derby Hospital</i>

Session 2

09:00 to 10:30	Hall 5
	Mammary Fold Session
	<i>Chairs: Miss Fiona Langlands & Miss Rebecca Lewis</i>
09:00 to 09:10	ESBQ – European options for training courses <i>Miss Fiona MacNeill, Royal Marsden Hospital, London</i>
09:10 to 09:25	Breast Screening: What Trainees need to know <i>Mr Giles Cunnick, Wycombe Hospital, High Wycombe</i>
09:25 to 09:40	Modifying breast cancer risks: Lifestyle advice in one stop clinics – does it make a difference? <i>Dr Sheila Stallard, Gartnavel Hospital, Glasgow</i>
09:40 to 10:00	Training a breast surgeon the Swiss way <i>Prof Walter Weber, Basel University Hospital, Switzerland</i>
10:00 to 10:15	Avoiding litigation as an early years consultant <i>Prof Phil Drew, Royal Cornwall Hospital Trust, Truro</i>
10:15 to 10:30	Discussion

Session 3

09:00 to 10:30	Hall 8
	Nursing Hot Topics
	<i>Chairs: Mrs Maria Noblet & Mrs Joanna Rowley</i>
09:00 to 09:20	Should breast care nurses play a role in promoting research to their breast care patients? <i>Ms Jean Mullin, Cambridge University NHS Foundation Trust</i>
09:20 to 09:40	What you need to know about Duty of Candour in the NHS BSP <i>Mrs Margaret Casey, New Cross Hospital, Wolverhampton</i>
09:40 to 10:00	Fear of recurrence <i>Prof Debbie Fenlon, Swansea University</i>
10:00 to 10:20	How Near infrared lymphofluoroscopy imaging is influencing the breast cancer population and helping lymphoedema <i>Mrs Jane Wigg, Lymphoedema Training Academy</i>
10:20 to 10:30	Discussion


Session 4

11:00 to 12:30	Hall 1
	Implant reconstruction infection and loss rates – time to act
	<i>Chairs: Prof Chris Holcombe and Miss Nicky Roche</i>
11:00 to 11:15	Unacceptable variation in implant loss rates: The i-BRA data <i>Ms Shelley Potter, Southmead Hospital & University of Bristol</i>
11:15 to 11:30	Getting it Right First Time: Breast reconstruction (England) 2014-17 <i>Miss Fiona MacNeill, Royal Marsden Hospital, London</i>
11:30 to 11:40	LIBRA: What is the impact of implant loss? <i>Dr Béré Mahoney & Prof Eleanor Bradley, University of Worcester</i>
11:40 to 11:55	What can we do better? Introducing a Surgical Site Infection Bundle <i>Miss Rachel Tillett, Royal Devon & Exeter Hospital</i>
11:55 to 12:05	Commentary <i>Baroness Delyth Morgan, Breast Cancer Now</i>
12:05 to 12:15	Culture change: Next steps for ABS members <i>Mr Ashu Gandhi, South Manchester University Hospital</i>
12:15 to 12:30	Discussion

Session 5

11:00 to 12:30		Hall 5
		Prize Papers
		<i>Chairs: Prof John Benson & Miss Michelle Mullan</i>
11:00 to 11:10	1.	HER-2 positive early breast cancer detected through the NHS Breast Screening Programme (NHSBSP) <i>Ian Boon, St James Institute of Oncology, Leeds</i>
11:10 to 11:20	2.	5 years of prepectoral breast reconstruction: outcomes and lessons learnt <i>Gareth Irwin, Manchester University NHS Foundation Trust</i>
11:20 to 11:30	3.	A 'best-practice' pathway for the acute management of mastitis and breast abscess enables non-specialists to "get it right first time" <i>Neill Patani, Imperial College Healthcare NHS Trust</i>
11:30 to 11:40	4.	Does immediate breast reconstruction delay the delivery of adjuvant treatment? The iBRA-2 prospective multicentre cohort study <i>Rachel O'Connell, on behalf of the iBRA-2 Steering Group and the Breast Reconstruction Research Collaborative</i>
11:40 to 11:50	5.	No difference in oncological outcomes after immediate or delayed reconstruction following mastectomy for breast cancer <i>Elizabeth Morrow, University of Glasgow</i>
11:50 to 12:00	6.	Extrinsic clotting pathway markers predict survival in early breast cancer <i>Hudhaifah Shaker, University of Manchester</i>
12:00 to 12:10	7.	Can surgery be avoided in select breast cancer patients with complete radiological response to neoadjuvant chemotherapy? <i>Anuradha Apte, Colchester Hospital University NHS Foundation Trust</i>
12:10 to 12:20	8.	A new dedicated Welsh online breast cancer predictive tool: CaFro <i>Leen Intabli, School of Management, Swansea</i>

Lunchtime session

12:40 to 13:40		Hall 5
	Advances in the management of ER positive HER2 negative breast cancer	
	<i>Educational symposium sponsored by Pfizer</i>	
	<i>Chair: Miss Julie Doughty</i>	
12:40 to 12:55		Who should be recommended for more than five years endocrine therapy? <i>Dr Daniel Rea, University of Birmingham</i>
12:55 to 13:10		Case presentations <i>Dr Christopher Poole, University of Birmingham</i>
13:10 to 13:25		Paradigm shift in the management of ER positive HER2 negative metastatic breast cancer patients <i>Dr Peter Schmid, Bart's Hospital</i>
13:25 to 13:40		Down-staging ER positive HER2 breast cancers <i>Mr Henry Cain, Royal Victoria Infirmary, Newcastle upon Tyne</i>

Lunch will be provided outside Hall 5 for those delegates attending this session

Monday 18th June 2018

Lunchtime session

13:05 to 13:50	Hall 8
	ABS Nurse Members' Meeting
13:05 to 13:10	Welcome <i>Mrs Joanna Rowley, ABS Nursing Trustee</i>
13:10 to 13:25	Post Paterson: A nursing perspective <i>Mr Mark Sibbering, ABS President</i>
13:25 to 13:40	Bullying and undermining in the workplace: Evidence that it affects our patients <i>Miss Leena Chagla, ABS Honorary Secretary</i>
13:40 to 13:50	Members' questions and discussion

Lunchtime session

13:15 to 13:45	Hall 3 (Balcony)
	Poster Prize Session
	<i>Chair: Mrs Katy Hogben</i>
	Oral presentation of the 6 best posters

Session 6

14:00 to 14:30	Hall 1
	Invited Lecture
	<i>Chair: Miss Fiona MacNeill</i>
	De-escalation of oncoplastic surgery <i>Dr Giuseppe Catanuto, Azienda Ospedaliera Cannizzaro, Catania, Italy</i>

Session 7

14:35 to 16:05	Hall 1
	Oncoplastic & Aesthetic Session
	<i>Chairs: Mr Lee Martin & Miss Sue Down</i>
14:35 to 14:50	Mastopexy: Pitfalls and how to avoid them <i>Mr Joe O'Donoghue, Royal Victoria Infirmary, Newcastle upon Tyne</i>
14:50 to 15:15	Dealing with complications and unhappy patients <i>Mr Simon Smith, Broomfield Hospital, Chelmsford</i>
15:15 to 15:25	Implant Registry Update <i>Mr Graeme Perks, Nottingham City Hospital</i>
15:25 to 15:50	Quantitative analysis of breast morphology <i>Dr Giuseppe Catanuto, Azienda Ospedaliera Cannizzaro, Catania, Italy</i>
15:50 to 16:05	Discussion

Session 8

14:35 to 16:05	Hall 5
	Society of Irish Breast Surgeons' Session: Young Women with Breast Cancer
	<i>Chairs: Mr Kieran Horgan & Mr Maurice Stokes</i>
14:35 to 14:50	Young women with breast cancer - outcomes and considerations <i>Ms Siun Walsh, Mater Misericordiae University Hospital</i>
14:50 to 15:05	The greater the risk the greater the reward: The speculation of resources in breast cancer care <i>Mr Mark Corrigan, Cork University Hospital</i>
15:05 to 15:20	Breast cancer and pregnancy <i>Ms Reem Salman, Craigavon Area Hospital</i>
15:20 to 15:35	Breast cancer surgery in young women <i>Prof Michael Kerin, University College Hospital Galway</i>
15:35 to 16:05	Panel Discussion

Session 9

14:35 to 16:05	Hall 8	
	Submitted papers	
	<i>Chairs: Miss Maria Bramley & Miss Anushka Chaudhry</i>	
14:35 to 14:45	9.	Neo-adjuvant versus adjuvant chemotherapy in early breast cancer: EBCTCG patient-level meta-analysis of long-term outcomes among 4756 women in 10 randomised trials <i>Paul McGale, Early Breast Cancer Trialists Collaborative Group, Oxford University</i>
14:45 to 14:55	10.	A systematic review of the impact of breast conserving surgery on cancer outcomes of multiple ipsilateral breast cancers (MIBC) - the case for a randomised trial <i>Zoe Winters, University College London</i>
14:55 to 15:05	11.	Indocyanine green (ICG) fluorescence mapping for sentinel lymph node (SLN) localisation in early breast cancer <i>Sujit Gnanakumar, Addenbrooke's Hospital, Cambridge</i>
15:05 to 15:15	12.	Utility of One-Step Nucleic Acid (OSNA) cytokeratin-19 amplification assay total tumour load (TTL) in survival prediction in primary operable invasive breast carcinoma <i>Nour Al-shurbasi, Sheffield Teaching Hospital</i>
15:15 to 15:25	13.	Chemotherapy utilisation in patients aged 50 years and over, diagnosed with invasive early breast cancer in England: Data from a population-based cohort <i>Melissa Gannon, NABCOP, Clinical Effectiveness Unit, Royal College of Surgeons of England</i>
15:25 to 15:35	14.	Outcomes of intraoperative versus pre-operative ultrasound localisation of impalpable breast lesions in the Cambridge Breast Unit <i>Primeera Wignarajah, Addenbrooke's Hospital, Cambridge</i>
15:35 to 15:45	15.	Enhanced pre-operative assessment of the axilla with grey-scale and contrast enhanced ultrasound (CEUS) may characterise a group of patients who can safely omit axillary surgery <i>Karina Cox, Maidstone and Tunbridge Wells NHS Trust</i>
15:45 to 15:55	16.	Neoadjuvant endocrine therapy; effect on phenotype and molecular profile in luminal breast carcinoma <i>Nahla Badr, University of Birmingham</i>

Monday 18th June 2018

Session 10

16:35 to 18:05	Hall 1
	Clinical Practice & Standards Session <i>Chairs: Mr Giles Cunnick and Mr Ashu Gandhi</i>
16:35 to 16:55	Defining the standards of care for breast cancer in the over 70s: An update from the National Audit of Breast Cancer in Older Patients <i>Prof Kieran Horgan, Leeds Teaching Hospitals NHS Trust</i>
16:55 to 17:25	NHS BSP & ABS Audit of Screen Detected Breast Cancers 2016-17 & Surgical KPIs <i>Mr Ashu Gandhi, South Manchester University Hospital</i>
17:25 to 17:50	Standardization of oncoplastic breast conserving surgery <i>Prof Walter Weber, Basel University Hospital, Switzerland</i>
17:50 to 18:05	TeaM Study <i>Ms Shelley Potter, Southmead Hospital & University of Bristol</i>

Session 11

16:35 to 18:05	Hall 5
	Hot topics I <i>Chairs: Mr James Harvey & Mr Sankaran Narayanan</i>
16:35 to 17:00	De-escalation of breast and axillary surgery <i>Dr Henry Kuerer, MD Anderson Cancer Center, Houston, USA</i>
17:00 to 17:25	Genomic profiling in clinical practice <i>Prof Mitch Dowsett, Royal Marsden Hospital, London</i>
17:25 to 17:45	Advances in immunotherapy <i>Dr Peter Schmid, Bart's Hospital</i>
17:45 to 18:05	Discussion

Session 12

16:35 to 18:05	Hall 8
	Living with and beyond breast cancer – taking the strategy forward <i>Chairs: Miss Penny McManus & Mrs Joanna Rowley</i>
16:35 to 17:05	Risk Stratification/Survivorship overview <i>Mr Steven Thrush, Worcestershire Royal Hospital</i>
17:05 to 17:35	Risk stratification in practice <i>Dr Liz Cox, Addenbrooke's Hospital, Cambridge</i>
17:35 to 17:55	Recovery package and Stratified follow-up for early breast cancer patients at UCLH <i>Ms Alia Nizam, University College London Hospitals NHS Foundation Trust & Ms Avril van der Loo, Macmillan Recovery Package Programme Manager</i>
17:55 to 18:05	Discussion

Come and chat with us on Stand 27

OneStop breast clinics

- Join our growing national network of approved consultants
- Working together with Cigna, AXA and other PMI providers

Genetic testing and counselling

- The only UK network of private registered genetic counsellors
- Recognised by all PMI providers
- BRCA1 & BRCA2 or 10 gene panel testing
- MyBreastRisk - risk assessment with 77 SNPs

www.BreastHealthUK.com

www.GeneHealthUK.com

SEBBIN PARIS
ESTHETIQUE & RECONSTRUCTION

Visit booth #21
to learn more about
our solutions for
breast reconstruction

Sebbin is a Paris-based medical device company with over 30 years experience in aesthetic and reconstructive surgery.



Recreating harmonious bodies
for a new vision of rebirth.

www.sebbin.com

Anatomical Breast Implants

Meso BioMatrix®
Acellular Peritoneum Matrix

Lipo'art solutions
for fat transfer and liposuction

New expander
with integrated valve
coming soon!



ABS Conference • 18th & 19th June 2018, ICC Birmingham

Tuesday 19th June 2018 – At a glance

	Hall 1	Hall 5	Hall 8
09:00 to 10:30	Session 13: Trial recruitment: Everyone's responsibility	Session 14: Submitted papers	
10:30 to 11:00	Tea and Coffee Break (Hall 3)		
11:00 to 12:30	Session 15: Clinical Leadership	Session 16: Neoadjuvant chemotherapy: Addressing the myths	Session 17: BRCA testing in breast cancer – where are we now? <i>An AstraZeneca UK Sponsored Symposium</i>
12:35 to 13:05	Session 18: Invited Lecture		
13:05 to 14:05	Lunch (Hall 3)		
14:05 to 14:35	Session 19: EJSO Lecture		
14:40 to 16:10	Session 20: Hormones and breast cancer	Session 21: Hot topics II	Session 22: Submitted Papers

Session 13

09:00 to 10:30	Hall 1
	Trial Recruitment – Everyone's Responsibility
	<i>Chairs: Mr Ramsey Cutress and Mr Stuart McIntosh</i>
09:00 to 09:15	Every patient deserves to be offered a clinical trial <i>Mrs Hilary Stobart, Independent Cancer Patients' Voice</i>
09:15 to 09:30	What explains the differences in trial recruitment between regions and units? <i>Dr Daniel Rea, University of Birmingham</i>
09:30 to 09:45	Trial recruitment: A team game <i>Mrs Glenda Paget, Belfast City Hospital</i>
09:45 to 10:00	Integrating trial recruitment into everyday clinical practice: What can we learn from other specialties? <i>Mr Simon Bach, University Hospitals Birmingham</i>
10:00 to 10:15	Starting trial recruitment, what are the first steps? <i>Prof Chris Holcombe, Royal Liverpool University Hospital</i>
10:15 to 10:30	Discussion

Session 14

09:00 to 10:30		Hall 5
		Submitted papers
		<i>Chairs: Mr Henry Cain & Miss Emma De Sousa</i>
09:00 to 09:10	17.	International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction <i>Zoe Winters, University College London</i>
09:10 to 09:20	18.	Characteristics and outcomes of older women with breast cancer undergoing breast reconstruction: Analysis of the Age Gap Trial <i>Irene Athanasiou, Doncaster and Bassetlaw Teaching Hospital NHS Trust</i>
09:20 to 09:30	19.	Sentinel lymph node biopsy (SLNB) in clinically node negative early breast cancer: A publication-level meta-analysis <i>Gurdeep Mannu, University of Oxford</i>
09:30 to 09:40	20.	Rates of local recurrence following skin-sparing mastectomy for breast cancer <i>Dorin Dumitru, Addenbrooke's Hospital, Cambridge</i>
09:40 to 09:50	21.	The effect of clinical and tumour factors on prognosis after contralateral breast cancer (CBC) in Northern Ireland (NI) <i>Colin McIlmunn, Centre for Cancer Research & Cell Biology, Belfast</i>
09:50 to 10:00	22.	Internal mammary nodes in DIEP reconstruction: Do they matter? <i>Tania Policastro, Royal Marsden NHS Foundation Trust, London</i>
10:00 to 10:10	23.	Treatment patterns for unilateral, non-invasive breast cancer in women diagnosed in England: Data from a population-based cohort <i>Yasmin Jauhari, NABCOP, Clinical Effectiveness Unit, Royal College of Surgeons of England</i>
10:10 to 10:20	24.	Validation of a nomogram using readily available clinicopathologic variables to predict Oncotype DX score in the preoperative setting <i>Roisin O'Cearbhaill, St Vincent's University Hospital, Dublin</i>


Session 15

11:00 to 12:30		Hall 1
		Clinical Leadership
		<i>Chairs: Mr Kieran Horgan & Miss Anne Tansley</i>
11:00 to 11:20		Compassionate and resilient leaders - They don't just pay lip service to a cause, they make a promise, act on it and keep it <i>Dr Wynne Thomas, Keele University</i>
11:20 to 11:40		A breast surgeon's perspective on management <i>Mr Martin Lee, Worcestershire Clinical Commissioning Groups</i>
11:40 to 12:00		Nursing leadership to improve patient outcomes and experience, and staff experience <i>Dr Shelley Dolan, Kings College Hospital NHS Foundation Trust</i>
12:00 to 12:15		Perspectives on moving into leadership roles <i>Miss Sisse Olsen, Royal Devon & Exeter Hospital</i>
12:15 to 12:30		Discussion

Session 16

11:00 to 12:30	Hall 5
	Neoadjuvant chemotherapy: Addressing the myths <i>Chairs: Miss Fiona MacNeill & Prof Jayant Vaidya</i>
11:00 to 11:15	Is complete pathological response related to improved survival? <i>Prof Michael Untch, Helios Hospital, Berlin, Germany</i>
11:15 to 11:30	Does neoadjuvant chemotherapy result in increased local recurrence rates? <i>Prof Michael Dixon, Western General Hospital, Edinburgh</i>
11:30 to 11:45	Does neoadjuvant chemotherapy allow more breast and axillary conservation surgery? <i>Prof Michael Untch, Helios Hospital, Berlin, Germany</i>
11:45 to 12:00	Can neoadjuvant results be translated to the adjuvant setting? <i>Dr Mark Harries, Guy's Hospital, London</i>
12:00 to 12:30	Case studies & Discussion

Session 17

11:00 to 12:30	Hall 8
	BRCA testing in breast cancer – where are we now? <i>This event is a non-promotional meeting sponsored and organised by AstraZeneca UK</i> <i>Chairs: Prof Philip Drew & Mrs Katy Hogben</i>
	Welcome and introductions <i>Prof Philip Drew, Royal Cornwall Hospital Trust, Truro & Mrs Katy Hogben, Imperial College Healthcare NHS Trust</i>
	Why test for BRCA? <i>Prof Samreen Ahmed, University Hospitals of Leicester NHS Trust & Mr Ashu Gandhi, University of South Manchester NHS Foundation Trust (Followed by panel discussion)</i>
11:00 to 11:05	
11:05 to 11:30	
11:30 to 11:50	Who to test for BRCA? <i>Dr Julian Barwell, University Hospitals of Leicester NHS Trust (Followed by panel discussion)</i>
11:50 to 12:15	How to test for BRCA? <i>Dr Zoe Kemp, Royal Marsden NHS Foundation Trust</i>
12:15 to 12:25	How can we improve testing in the UK? <i>Panel Discussion</i>
12:25 to 12:30	Summary and close <i>Prof Philip Drew, Royal Cornwall Hospital Trust, Truro & Mrs Katy Hogben, Imperial College Healthcare NHS Trust</i>

Session 18

12:35 to 13:05	Hall 1
	Invited Lecture
	<i>Chair: Miss Julie Doughty</i>
	Challenges of surgery in locally advanced breast cancer: Stretching beyond limits <i>Prof Diptendra Sarkar, Institute of Post Graduate Medical Education and Research, Kolkata, India</i>

Session 19

14:05 to 14:35	Hall 1
	EJSO Lecture
	<i>Chair: Mr Mark Sibbering</i>
	Stress and burnout in medical professionals <i>Dr Henry Kuerer, MD Anderson Cancer Center, Houston, USA</i>

Session 20

14:40 to 16:10	Hall 1
	Hormones and breast cancer
	<i>Chairs: Miss Leena Chagla & Mrs Clare Fowler</i>
14:40 to 15:00	HRT – misconceptions, risks and benefits <i>Mr Tim Hillard, Poole Hospital NHS Foundation Trust</i>
15:00 to 15:20	HRT and Breast Cancer: Its use before and after diagnosis <i>Miss Jo Marsden, King's College Hospital NHS Trust</i>
15:20 to 15:40	The management of oestrogen deficiency in breast cancer survivors <i>Mr Michael Marsh, Kings College Hospital NHS Trust</i>
15:40 to 15:55	Contraception choices after diagnosis <i>Mr Michael Cust, Royal Derby Hospital</i>
15:55 to 16:10	Discussion

Session 21

14:40 to 16:10	Hall 5
	Hot Topics II
	<i>Chairs: Mr Richard Johnson & Miss Cliona Kirwan</i>
14:40 to 15:00	Using behavioural economics in health: Cancer screening and beyond <i>Ms Sarah Huf, The University of Pennsylvania</i>
15:00 to 15:20	Get ready for GiRFT <i>Miss Tracey Irvine, Royal Surrey County Hospital</i>
15:20 to 15:40	Restrictions on breast reconstruction services in England – research from Breast Cancer Now <i>Ms Sally Greenbrook, Breast Cancer Now</i>
15:40 to 15:55	Bisphosphonates – for whom and for how long? <i>Prof John Benson, Addenbrooke's Hospital, Cambridge</i>
15:55 to 16:10	Discussion

Tuesday 19th June 2018

Session 22

14:40 to 16:10		Hall 8
		Submitted papers
		<i>Chairs: Miss Karina Cox & Mr Laszlo Romics</i>
14:40 to 14:50	25.	Targeted axillary lymph node dissection improves the accuracy of axillary assessment <i>Deyana Oweis, Royal Victoria Infirmary, Newcastle upon Tyne</i>
14:50 to 15:00	26.	Exploring the effects of an exercise programme on women with breast cancer <i>Ruth McCrea, Princess Alexandra NHS Trust</i>
15:00 to 15:10	27.	Neoadjuvant chemotherapy and surgical planning: Survey of practice, attitudes and opinions around the UK <i>Siobhan Laws, Royal Hampshire County Hospital, Winchester</i>
15:10 to 15:20	28.	Evaluation of the Breast Cancer Haven support service embedded within a NHS breast unit <i>Caroline Hoffman, Breast Cancer Haven, London</i>
15:20 to 15:30	29.	The role of pectoral nerve (Pecs) blocks in a day case mastectomy service <i>Ashleigh Bell, Northumbria NHS Foundation Trust</i>
15:30 to 15:40	30.	An audit of referral patterns to a Breast New Referral Clinic <i>Susie Laking, Nottingham Breast Institute</i>
15:40 to 15:50	31.	Preference for Quality of Life versus Length of Life in older women making treatment decisions in early breast cancer <i>Anne Shrestha, University of Sheffield</i>
15:50 to 16:00	32.	Relieving the pain of the New Referral Clinic <i>Lisa Sawers, Nottingham Breast Insitute</i>



Webcasts of most of the presentations from the conference will be available shortly on the ABS website

www.associationofbreastsurgery.org.uk

Conference Evaluation

Delegates are requested to complete their conference evaluation online via the App or the ABS website

www.associationofbreastsurgery.org.uk

A free delegate registration for the ABS Conference 2019 is on offer to the first person picked at random from those completing the online evaluation by the 8th July

OVERSEAS SPEAKERS

Dr Giuseppe Catanuto



Dr Giuseppe Catanuto is a consultant oncoplastic breast surgeon at Ospedale Cannizzaro in Catania, Italy. From 2006 to 2012 he served in the same position at Humanitas-Catania where he developed a specific expertise in therapeutic mammoplasties and conservative mastectomies. In the same period he worked as a consultant of the "Scuola di Oncologia Chirurgica Ricostruttiva" - Milan, Italy, founded by Maurizio Nava. On behalf of this organisation and jointly with partners from the Royal Marsden Hospital and Addenbrokes Hospital he coordinated the International Fellowship "G. Querci della Rovere". In April 2017 he founded a new organization called "G.Re.T.A.", Group for Reconstructive and Therapeutic Advancements and he is currently the Executive Chairman. He is also a professor at the "Master in Oncoplastic Surgery and Integrated Treatments" at the University of Genova.

His research areas are: Oncoplastic surgery of the breast; development and validation of a questionnaire on quality of life after breast reconstruction (BRECON -23) on behalf of the EORTC QoL group; decision making in breast surgery and mathematical modelling of breast shape.

Dr Catanuto started his career in breast surgery as a fellow of Mr Guidubaldo Querci della Rovere at the Royal Marsden Hospital in Sutton at the beginning of the last decade.

Dr Henry Kuerer



Dr Henry Kuerer plays a leading role in MD Anderson's world-renowned breast care group as a recognized cancer surgeon and researcher who specializes in the multidisciplinary care of patients with breast cancer.

Recruited to MD Anderson to establish a premier program to train breast cancer surgeons of the future, he is now a Distinguished Endowed Professor of Surgery, the Executive Director of Breast Programs and the Director of the Breast Surgical Oncology Training Program. He maintains a busy clinical research program and is Principal Investigator for the newly expanded national cooperative group NRG Oncology at MD Anderson, is on the editorial board of several clinical journals, and is active with the American Society of Breast Surgeons and the Society of Surgical Oncology. Dr Kuerer is heavily involved with the MD Anderson Cancer Network clinical expansion in terms of comprehensive assessment, benchmarking, and review of potential new partners and ongoing member hospital and programmatic relationships nationally and internationally.

Dr Kuerer is a regularly invited speaker at academic, national, and international meetings and has authored or coauthored more than 400 peer-reviewed scientific reports, editorials/commentaries, and text chapters. Dr Kuerer is Editor-in-Chief of the definitive McGraw-Hill textbook, Breast Surgical Oncology. Originally from New Jersey, Dr Kuerer attended Rutgers College and received his MD and PhD in Molecular Immunology at the State University of New York Health Science Center in Brooklyn, trained in general surgery at the Mount Sinai School of Medicine in New York City, completed his fellowship training at MD Anderson and also practiced at the University of California-San Francisco

Prof Diptendra Sarkar



Diptendra K Sarkar is a Professor of Surgery and chief of the Breast Surgery and Research Unit at IPGMER, Kolkata, India. He was awarded the prestigious GB Ong award by the Royal College of Surgeons of Edinburgh for securing the highest position in FRCS exam in 2000. He is currently the President of the Association of Breast Surgeons of India and the Honorary Secretary of Asian Society of Mastology. Prof Sarkar is the Associate Editor of Indian Journal of Surgery and Journal of Indian Medical Association. He is an international Tutor-examiner with the Royal College of Surgeons of Edinburgh.

He is a member of the working group committee on Breast Cancer screening in India and has been the international resource person for early diagnosis in breast cancer for Bangladesh. He is presently a member of the Governing Council of Association of Surgeons of India.

His areas of interest include research in prognostic markers and locally advanced breast cancer. He has written more than 40 peer-reviewed articles and contributed to 3 book chapters. Prof Sarkar has delivered more than 200 invited talks. His basic research on cox-2 receptors and role of aspirin has been highly acclaimed internationally. Oncoplasty in LABC, the major problem in most developing countries, is another area in which he has been working with various innovations.

He is guide for PhD and post Doctorate program with various universities and has been the Principal Investigator of various projects run by ICMR and DST.

OVERSEAS SPEAKERS

Prof Michael Untch



Michael Untch is Professor of Medicine and Head of the Clinic for Gynecology, Gynecologic Oncology and Obstetrics and Head of the Interdisciplinary Breast Cancer Center at the HELIOS Klinikum Berlin-Buch, Berlin, Germany. He graduated from Medical School, Ludwig Maximilians University Munich and started his career in Gynecology and Gynecologic Oncology at the University of Muenchen-Grosshadern followed by post doctoral research at the Department of Gynecologic Oncology, University of Miami, School of Medicine.

In the Clinic for Gynecology, Gynecologic Oncology and Obstetrics the patient numbers per year are: 2700 deliveries, including level 1 care in the perinatal center, 3500 gynecologic surgeries, including surgery for breast cancer, ovarian, cervical, and endometrial cancer.

Professor Untch is author and co-author of more than 600 scientific publications, some of them in Journals with a high reputation like New Eng J Med, Lancet, J of Clin Oncology. His main research interests are new therapies in breast cancer, new surgical techniques in gynecologic oncology, mutation spectrum in familial breast and ovarian cancer, prognostic and predictive factors in breast cancer.

Prof Walter Weber



Walter Weber was born in New York in 1973, even though he has spent most of his life in Switzerland. He studied medicine at the University of Basel, where he continued to work as a resident, attending and currently as chief of the breast surgery service. He spent more than two years in the lab in the field of tumour immunology at his home University and at the Johns Hopkins Medical Institutions. He trained to become a SSO accredited breast surgeon during a breast fellowship with Monica Morrow at Memorial Sloan Kettering Cancer Center.

Walter Weber's clinical research interest focuses on surgical RCTs in the field of surgical site infection and de-escalation of breast cancer surgery. He has been the principal investigator of several international multicentre RCTs and plans the initiation of a potentially practice changing trial in July 2018 in 5 countries/47 centres. His second clinical research focus is oncoplastic surgery. He founded the Oncoplastic Breast Consortium (www.oncoplasticbc.org) with the aim of bringing experts together to address controversial topics, offering training opportunities and performing clinical research.

Walter Weber's translational research interest focuses on multidisciplinary projects in the field of tumour heterogeneity. He co-founded the Basel Breast Consortium (www.baselbc.org) to build bridges between the laboratories, clinical disciplines and the pharmaceutical industries in the Basel area. He currently is the principal investigator of a systems biology project that aims to identify the cell subpopulations responsible for tumour progression (www.systemsx.ch/metastasix).

List of Exhibitors

Trade Exhibition

The Exhibition will be held in Hall 3 and will be open at the following times:

Monday 18th June 2018: 07:45 to 18:30

Tuesday 19th June 2018: 08:30 to 14:05

Advantech Surgical Ltd

Advantech Surgical and Belle are pleased to be showcasing the following products:

- MicroAire Power Assisted LipoPlasty system (PAL)
- MicroAire LipoFilter large volume disposable, fat harvesting and processing system that is easy, fast and entirely closed
- Deep Care by INDIBA – Improved healing for smokers and diabetics
- PureGraft small and large volume fat grafting system
- Fat transfer Instrumentation by Tulip Medical Products.

Stop by our stand to learn more about these and other products.

Allergan Ltd

Allergan are delighted to introduce Healthcare 21 as the exclusive partners for their breast surgery portfolio in the UK, Ireland, Germany and Austria. On display at the HC21 stand are the;

- Natrelle™ Breast Implants
- Artia™ Acellular Dermal Matrix
- Strattice™ Acellular Dermal Matrix
- Revolve™ Fat Grafting Device
- Keller Funnel® 2

Amoena

Established in 1975, Amoena is the world's leading breast care brand.

As the industry pioneer, Amoena combines technology with supreme comfort, offering an extensive range of bras, swimwear and breast symmetry products.

We work closely with both breast-operated women and surgeons to ensure our recovery care garments reflect the latest surgical techniques and knowledge. The right compression and support is critical in the days following surgery, to help decrease post-operative discomfort, reduce stress on the skin closures and minimise swelling. Our recovery care bras are ideal for breast augmentation, reconstruction and reduction procedures, to aid healing and ensure a perfect result.

Astrazeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.

Blackwell's

Blackwell's have been supplying specialist publications and academic books for over 130 years and are a contracted supplier to the NHS and Department of Health. Blackwell Exhibitions specialises in bringing event specific books to the UK Medical meetings, offering delegates a range of titles seldom found together elsewhere.

Breast Cancer Care

Breast Cancer Care is the only UK-wide charity providing specialist information and support for people affected by breast cancer and the healthcare professionals who care for them. Our free services include support over the phone with a nurse or someone who's had breast cancer and had a similar experience, reliable patient information written by specialist nurses and reviewed by healthcare professionals and people with breast cancer, our welcoming online forums, and local group support for people with a primary and secondary breast cancer diagnosis.

Breast Cancer Haven

Breast Cancer Haven is a national charity that supports women through their breast cancer treatment. When breast cancer tries to rob a woman of her individuality, her confidence or her strength, we provide the free tailored package of emotional, physical and practical support that helps her hold on to them.

We support women and their families via a network of six welcoming centres around the UK and through an expanding network of other services. We're there to provide women with breast cancer the support that treatment alone can't.

List of Exhibitors

Breast Cancer Now

We're Breast Cancer Now, the UK's largest breast cancer charity – and we're dedicated to funding research into this devastating disease. We believe that if we all act now, by 2050, everyone who develops breast cancer will live – and live well. But we'll only reach that point by working in a new, collaborative way. We're bringing together all those affected by the disease to improve the way we prevent, detect, treat and stop the disease. Together, we can create a future without fear of breast cancer.

BreastHealth UK

BreastHealth UK (stand 27) is a clinically-led early cancer diagnostic company with a difference:

MyBreastRisk – the first breast cancer risk assessment test that includes genetic (77 SNPs), family history & lifestyle factors. This underpins our risk-stratified breast cancer screening programme for the private and corporate markets

We now operate a network of private diagnostic OneStop Breast clinics for several large UK PMI companies as well as the self-pay market.

Through our sister company, GeneHealth UK, we also offer genetic testing with pre- and post-test counselling for BRCA1& 2 or BreastGene, a panel of 10 clinically relevant breast cancer genes.

DAAX LTD

UK / Ireland representatives for FAXITRON – leading manufacturers of innovative solutions for digital specimen radiography.

BioVision for surgical radiography enabling a surgeon to accurately determine margin assessment within 10 seconds minimising the risk of re-excision and saving at least 20 minutes per procedure

CoreVision for breast care units to identify calcification within needle biopsy

PathVision for histopathology where the large field of view provides imaging capability from small wax block assessment to full mastectomy and fetal specimen imaging

"VISION" systems – simple to operate providing clinicians with a unique level of image quality

For information visit: www.daax.co.uk

Eurosurgical Ltd

Eurosurgical Ltd were founded in 1988 as a specialist UK based company for new and established surgical

devices, specializing in breast, reconstruction and plastic surgery. Products include, TIGR Mesh a 100% synthetic long-term resorbable matrix made from two well-known suture materials that are strong over 9 months and fully disappears over 2 years ideal for both sub-muscular support and pre-pectoral IBR. Insorb subcuticular staple device for rapid and cosmetic wound closure, Fat Grafting equipment and cannula for small to large fat harvesting, including Lipivage and Aquavage and the excellent RecoBra for all post-op breast procedures.

FaHRAS

FaHRAS supplies a sophisticated evidence-based software system which enables a user to run a variety of analyses against their family history to quantify their risk of developing breast cancer.

Flat Friends

Flat Friends supports women living without breast reconstruction after mastectomy, including those who face such decisions now or in the future, due to a breast cancer diagnosis or preventative surgery

GC Aesthetics Ltd

Our company is the UK's leading manufacturer of breast implants. We supply thousands of implants every year, changing lives around the globe. We have over 60 years combined market presence with Nagôr and Eurosilicone products. Overall we have 24% for the world market excluding the US, up from 18% just 3 years ago. We work in partnership with the medical community to continually develop high quality products and services that meet both surgeons' and women's needs. As a global leader in the female aesthetics industry, GC Aesthetics not only provides over 1100 products across our brands Eurosilicone® and Nagôr®; but also delivers services to help women make informed choices.

Genomic Health

Genomic Health is the world's leading provider of genomic-based diagnostic tests that help optimise cancer care, including addressing the overtreatment of the disease. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California with the UK office in London and international headquarters in Geneva, Switzerland. For more information, please visit www.genomichealth.co.uk

List of Exhibitors

Healthcare 21

Healthcare 21 (HC21) are delighted to be a corporate sponsor of ABS and join you in Birmingham this year.

We are one of the largest Medical Device Distributors in Northern Europe and exclusively distribute the Allergan breast surgery portfolio in the UK, Ireland, Germany and Austria.

Come and join us on stands 24 and 30 to discuss our market leading breast surgery portfolio and try your hand at our Keller Funnel-Implant game!

The portfolio includes;

- Natrelle™ Breast Implants
- Artia™ Acellular Dermal Matrix
- Strattice™ Acellular Dermal Matrix
- Revolve™ Fat Grafting Device
- Keller Funnel® 2

Hologic

Hologic is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Hologic continues to drive innovation in breast health to provide high-quality mammograms for physicians, supplying them with the most accurate information. Our 3D Mammography™ exam is proven to offer better, earlier, breast cancer detection compared to conventional mammography alone, enabling physicians to provide patients with earlier diagnosis and reduced chance of call backs. For patients we are delivering minimally invasive biopsy solutions that enable an improved patient experience without clinical compromise.

Ideal Medical Solutions

Ideal Medical Solutions are a UK distributor, with an extensive range of breast surgery products.

Please visit our stand to find out further information on the following clinically proven products and to collect your free samples: Onetrac® single use retractor with built in LED light source, Galaflex® mesh, for soft tissue support and reinforcement, Filtron® Fat Transfer and the full range of single use cannulas, Tissue Aid - tissue adhesive, Penblade safety scalpels and Viscot surgical marker pens.

IGEA Medical

Through extensive research IGEA have developed CLINIPORATOR™ to deliver Electrochemotherapy. It has been well documented that cutaneous metastases have the greatest impact on a patient's day to day quality of life. CLINIPORATOR™ offers patients with cutaneous and subcutaneous

metastases an option to improve quality of life when perhaps other treatments have been exhausted, and can be used alongside conventional chemotherapy.

Independent Cancer Patients' Voice

Independent Cancer Patients' Voice (ICPV) is a patient advocate group led by patients for patients. We bring the views and experience of cancer patients, their family and carers, to the cancer research community. We believe that clinical research is improved by patients being partners with clinicians and healthcare professionals, rather than passive recipients of healthcare.

ICPV has over 60 members with a considerable diversity of cancer diagnoses and a good geographical spread. Most are patients but some are family members or carers.

Lockton

Lockton has a wealth of experience in the private healthcare sector where we deliver bespoke, flexible and sophisticated solutions. Our Medical Indemnity cover comes with a wide range of benefits that are defined specifically for you and your practice's needs. Most importantly our cover is contractual, not discretionary, meaning that you are guaranteed to be covered in the event of any claim made and supported through a legally enforceable contract.

Mammary Fold

The Mammary Fold is the UK Breast Surgery trainees' association. It is run by trainees within the UK with an interest in Breast and Oncoplastic Breast Surgery under the auspices of the Association of Breast Surgery. It aims to support its members throughout their career and we have regional representatives at a local level to be easily accessible to all. Furthermore, the Mammary Fold Academic Committee provides opportunities for trainees to engage in research with an expanding portfolio of national collaborative trainee-led breast research studies. We welcome all trainees interested in Breast Surgery to speak to us at the stand and join the Mammary Fold by contacting themammaryfold@gmail.com

Medasun Ltd

Medasun Ltd is a UK family owned business established in 2004 based in Rutland.

Medasun distributes 25 years of Marena design experience breast surgery bras to the UK and Irish health sectors.

Patients are happy to wear Marena bras 24 hours a day for 6 weeks, as they keep their shape, power-stretch and softness. Classic Marena bras are easy to fit, with one underbust measurement. A well fitted,

A vision of excellence

BioVision
from **faxitron**

Visit us at
stand No. 1

daax

www.daax.co.uk | info@daax.co.uk
+44 (0)370 979 9110



EndoPredict®

A breast cancer recurrence test for patients with newly diagnosed ER+, HER2- early stage breast cancer

INCLUDED in international guidelines (ASCO, ESMO, St. Gallen, EGMT, AJCC, AGO)
VALIDATED in four large clinical studies with more than 3,100 patients^{3,4,5}
USED to guide treatment selection in more than 20,000 patients worldwide

EndoPredict accurately identifies more patients who may safely forgo chemotherapy^{1,2}

- Trained and validated on 10-year outcomes data
- Consistent risk of recurrence in **node negative** and **node positive** patients classified as low risk
- Integrates 12-gene molecular score with tumour size and nodal status

1. Sestak I, Buis R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol*. Published online February 15, 2018.
2. Dubsky P, Filipits M, Jakesz R, et al. EndoPredict Improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. *Ann Oncol* 2013; 24: 640-647
3. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive HER2- negative breast cancer adds independent information to conventional clinical risk factors. *Clin Cancer Res*. 2011; 17(18): 6012-6020
4. Martin M, Brase JC, Calvo L, et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. *Breast Cancer Res* 2014; 16:R38
5. Buis R, Sestak I, Kronenwetter R, et al. Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for prediction of risk of distant recurrence after Endocrine therapy. *J Natl Cancer Inst*. 2016; 108(11).

myriad
WHEN DECISIONS MATTER

Myriad Genetics Ltd
The Stanley Building
7 Pancras Square
London N1C 4AG
info@myriadgenetics.co.uk
www.endopredict.com

List of Exhibitors

comfortable, Marena bra with anti-microbial and breathable features helps patients recover from their breast surgery.

Medasun is proud to sponsor the ABS, we look forward to meeting you in Birmingham.

Mentor

As a member of the Johnson & Johnson family of companies, patient safety is our priority at Mentor. That's why we're committed to delivering the highest standards of quality and increased patient outcomes.

Mentor's 10 year data demonstrates our passion to deliver safe products that offer high quality, reliable and state-of-the-art design to enhance breast aesthetic procedures. We are determined to continue to provide objective, clinical information about breast implant safety.

To our Mentor customers and patients, we pledge our commitment to excellence.

MIS Healthcare

MIS Healthcare is a UK based exclusive distributor for world leading medical manufacturers, providing state of the art products ranging from high end medical imaging diagnostic equipment, PACS/RIS, medical consumable and diagnostic instruments.

Our dedication and many years of experience has allowed us to partner with world leading manufacturers such as Samsung, Novarad, Kubtec, Planmed, Riester Medical Diagnostic Equipment.

Technology continuously evolves and so do we, at MIS Healthcare we remain driven by our passion for providing excellent imaging solutions in the interest of accurate diagnosis, perfecting those solutions and delighting our customers.

Myriad Genetics Ltd

Myriad Genetics, a leading molecular diagnostic company founded in 1991 is dedicated to saving and improving lives by discovering and delivering valued, transformative tests across all major diseases.

Myriad's testing portfolio is uniquely qualified to address the following key areas in oncology – cancer prevention, early diagnosis, the development of new treatments and optimisation of current treatments by personalising and increasing effectiveness. Myriad International operates a state of the art laboratory in Munich, Germany.

Contact Myriad UK and Ireland

The Stanley Building, 7 Pancras Square London N1C 4AG, United Kingdom

Office: 00 44 (0) 203 897 6620/6621
info@myriadgenetics.co.uk
www.myriadgenetics.co.uk

National Audit of Breast Cancer in Older Patients (NABCOP)

The National Audit of Breast Cancer in Older Patients (NABCOP) evaluates the quality of care for women with breast cancer, aged 70 years or over, in England and Wales. It investigates the management for older patients with breast cancer, compared with women diagnosed with breast cancer aged 50-69 years, and highlights potential areas for improvement. NABCOP's 2018 Annual Report describes the results from the prospective audit of women diagnosed between from 2014 to 2016 in England and Wales, describing how patterns of care differ between women in the younger and older age groups.

For further information, please visit:
www.nabcop.org.uk

Oncology Systems Ltd

Oncology Systems Limited specialises in supplying radiotherapy technology for the treatment of cancer and is the exclusive distributor of the Carl Zeiss INTRABEAM system throughout the UK. Although primarily used for the treatment of breast cancer at the time of breast conserving surgery (TARGIT), potentially negating the need for several weeks of external beam radiotherapy treatment, the INTRABEAM system also has applications in the following areas: head and neck, colorectal, kypho, GYN and superficial. Stop by the OSL booth to find out more.

Operating Room Systems Ltd

Operating Room Systems Ltd., specialise in the supply of surgical equipment and associated consumables to hospitals and private clinics across UK and Ireland. Our product portfolio spans across the clinical spectrum with particular specialism within the area of Minimally Invasive Surgery.

Within Breast Surgery we offer a range of solutions for effective retraction combined with delivery of light to the operative field. As sole distributor for World of Medicine, we represent Gamma Finder® in this market. The Gamma Finder® probe is best suited for Sentinel Node and Parathyroid Localization in Surgical Oncology. Its unique design puts simplicity and accuracy at the surgeon's fingertips. The Gamma Finder® probe will detect and give a numerical indication and an acoustic signal when in proximity of a gamma ray emitting source. Compact, lightweight and versatile, the Gamma Finder® probe is easily transported from operating room to operating room in its own sturdy carry case. We introduce the latest

List of Exhibitors

model, Gamma Finder III® to the UK & Ireland market at conference this year.

Our philosophy at Operating Room Systems is clear. We are committed to building long term sustaining relationships with our customers, bringing them innovation, value and quality; along with delivering effective technical support and robust after sales service provision.

Pfizer

Pfizer: Working together for a healthier world

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at www.pfizer.co.uk

pfm medical

pfm medical UK Limited is the UK subsidiary of pfm medical ag.

We are specialist manufacturers and distributors of vascular access, wound drain, histology and surgical implant (titanized mesh) products. Located in the Cheshire countryside, we are committed to supplying high quality products to the NHS, Private Hospitals, Research and Development Centres, Laboratories, Veterinary Surgeries, Pharmaceutical and all other care services.

We have been established since 2007 and have a strong team of clinical sales consultants and expert support staff.

Q Medical

Q Medical Technologies Ltd is an independent UK company founded in 2004. The company occupies premises in Cumbria. In May 2009, Q Medical Technologies Ltd joined the Q Technologies group of

companies.

Q Medical distributes and markets a range of medical devices. These include SurgiMend (ADM) Polytech Breast Implants, Ellman Radio Frequency machines, Ellman Medical lasers and Infection Control and Pain Relief products.

We have full representative coverage within the UK and Ireland. Our highly trained and skilled representatives also provide in house clinical training on all products. Additionally we have specialist training available from registered clinicians who provide specialist training as and when required.

Raise

Raise Healthcare is specialist distributor for UK market specialising in Biologic meshes and Fat grafting system.

Manufactured in Germany, our products for Breast Reconstruction include BRAXON for pre pectoral reconstruction and NATIVE for sub pectoral reconstruction.

BRAXON is patented and world's first ADM for Pre Pectoral Breast Reconstruction for complete coverage of the breast implant without detaching the Pectoralis Muscle.

Regenerys Ltd

Regenerys Ltd offers the Adiposet service for HTA compliant cryopreservation of autologous adipose tissue to improve outcomes and improve the patient pathway where multiple lipomodellings are required to reconstruct the breast. One single harvest is taken in the first procedure. Some tissue is employed at harvest and the remainder is stored using a bespoke cryopreservation method that retains tissue viability. Tissue is returned thawed in multiples of 35ml and injected into the breast. This approach saves money and reduces risk. To discuss further please email sue.oliver@regenerys.com.

Roche

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life, safety and survival of patients. Twenty-eight medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

List of Exhibitors

Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics. For more information: www.roche.co.uk

All trademarks used or mentioned in this release are protected by law.

Sebbin UK Ltd

Sebbin is a Paris-based medical device company focused on reconstructive and aesthetic surgery. Sebbin has supplied high quality devices for over 30 years and is present in nearly 60 countries worldwide.

Our comprehensive product portfolio includes silicone breast implants, a unique biological scaffold and a full range of disposable lipofilling devices.

We are one of only 3 companies to offer 10-year clinical data on our breast implants. Our new 10-year study is currently the largest prospective breast implant study in the world.

Visit booth #21 and our experienced team will introduce you to our portfolio.

Smith & Nephew

Smith & Nephew is a diversified advanced medical technology business that supports healthcare professionals in more than 100 countries to improve the quality of life for their patients. We do this by taking a pioneering approach to the design of our products and services, by striving to secure wide access to our diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems. Smith & Nephew provide a range of products for preventing, treating and managing wounds.

Please visit us at stand 4 to see how we continue to support our customers to improve outcomes, constantly striving to create value for healthcare professionals, patients and payers.

www.smith-nephew.com

E-mail: advice@smith-nephew.com

Southern Scientific

Southern Scientific has many years of experience and expertise working in the specialist health sector. In addition, as part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide. We are the UK manufacturer of the C-Trak Gamma Probe System which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer. We are also the UK supplier of preloaded needles with I-125 seeds for tumour localisation.

Sysmex UK Limited

Serving customers for 50 years, our mission is to shape the advancement of healthcare by delivering technological leadership in diagnostic science that makes a genuine difference to the health of people worldwide. In Oncology, Sysmex has been focusing on improving breast cancer management through standardised, molecular lymph node analysis with the NICE approved OSNA® system and radiation-free detection of sentinel lymph nodes with the Sentimag/Sienna® system. Our latest addition, Magseed®, focuses on non-palpable lesion localisation without guide wires. Magseed® can be placed 30 days prior to surgery and accurately removed with the guidance of Sentimag®. Magseed® is available to everyone, everywhere.

UK Surgical

Specialist in surgical-retraction. We manufacture both self-retaining and hand held retractors required in such procedures as Axillary Node Clearance, Single and Bilateral Mastectomy, LD Flap and Skin sparing procedures where surgical access and illumination is required.

We specialize in producing retraction where or when no surgical assistance is required or available. We have significantly improved the design and eliminated potential problems associated with patient safety from the use of other retraction devices on the market.

Our range of Supercut scissors are the finest available and can be re-sharpened up to 5 times giving you excellent value for money in these difficult times.

Simply put, you cannot buy a better retractor or scissor.

Thuasne

SILIMA is Thuasne's flagship brand within breast care. A trusted supplier to the NHS with over 40 years' experience in mastectomy care, the SILIMA range comprises a comprehensive selection of natural-feel breast forms, well-fitting bras and lingerie, and other post-surgery mastectomy products.

University of East Anglia

Postgraduate students within UEA's Faculty of Medicine and Health Sciences enjoy an innovative network of medical and healthcare professionals, focused on delivering the highest quality of care and addressing some of the world's most critical health challenges head on.

The UEA Master of Surgery (MS/MCh) is, we believe, the highest qualification in Oncoplastic Breast Surgery worldwide, offering a rigorous, tailored

List of Exhibitors

and flexible online solution to the training needs of surgeons progressing in this super-specialist field. Our aim is to prepare, assess and qualify students through consideration of realistic cases to develop consultant-level critical thinking.

Vacuum Assisted Excision Working Group

A new resource app has been created by the VAE working group to provide support and guidance for clinical teams looking to perform Vacuum Assisted Excisions. Addressing guidelines, protocols and pathways, coding, education and patient information, established centres have contributed their best practice resources to aid in the development of this new tool. The VAE resource pack is available free now to order or for download.

Womanzone

Our mission is to meet the ever changing needs of today's women!

Womanzone would like to welcome you to our exciting range of Light, Soft and Satin Breast Prosthesis. Providing you with choice despite the type of treatment received, preference likes or dislikes. All our products are available on NHS Contract.

For 2018 we have launched our NEW Custom made Breast Prosthesis, which is new to the UK and NHS Approved.

Womanzone offer credited training sessions, designed to suit individual/ trust needs within the NHS for all professions from ward level to Breast Care Nurses in the specialised fitting of Prostheses and Bras. We have over 40 years' experience in understanding the needs of women after breast surgery.

The ABS would like to thank all exhibiting companies for their support of this meeting

MENTOR® CPG™ Gel Breast Implants

10 YEARS
THAT SHAPED BREAST
AESTHETICS

A ten year multicentre FDA Core Study.¹



1. Mentor Worldwide, LLC. MemoryShape® Post-Approval Cohort Study (formerly Contour Profile Gel Core Study) Final Clinical Study Report. 02 June 2015. © www.mentormedical.co.uk

General information

Registration

Registration will be open in the Foyer at the following times:

Monday 18th June 2018: 07:45 to 19:30

Tuesday 19th June 2018: 08:30 to 16:30

In the interests of security delegates should wear their name badges at all times whilst in the conference centre.

Lunch and Refreshments

Lunch and refreshments will be served in Hall 3 at the times listed in the programme.

Media Suite

An A/V Preview Room is available in the Media Suite for the duration of the meeting. Speakers are requested to hand their presentations into the room on arrival.

ABS Conference App

The ABS Conference App can be downloaded from your app store. It includes programme information, a 'my schedule' facility, speaker information, delegate list and exhibitors list. You can view the abstracts via the Conference App and also give your conference feedback.

Image and information consent

Photography

A photographer will be taking images of the conference during the event for use by the ABS at this meeting, in future publications and on its website. If you do not wish to have images of yourself used by the ABS please let Lucy Davies know by e-mail at lucydavies@absgbi.org.uk

Posters

The poster presentations will be displayed in Hall 3 (including on the Balcony) for the duration of the meeting. Please can all poster presenters mark and store their poster tubes in the boxes provided in the room. These will be stored at registration. Posters should be removed between 13:50 and 14:05 on Tuesday 19th June and can be stored at registration for the afternoon session if required. Posters left on the boards after this time will be removed and the ABS cannot be responsible for their safe return.

Cloakroom

A cloakroom and luggage store will be available on Level 3 for the duration of the meeting.

Wi-Fi

Delegates wishing to use the Wi-Fi should log onto '_The ICC Free Wifi' and accept the terms and conditions.

Prayer Room

A prayer room is available for the use of delegates on level 3 near to Starbucks. Members of the hosting team are available to direct delegates to the room.

Social events

Drinks reception and Poster viewing

A drinks reception and poster viewing will be held in Hall 3 on Monday 18th June from 18:05 to 19:45.

For any delegates wishing to watch England v Tunisia in the World Cup there will be a plasma showing the game on the balcony area in Hall 3 and in the foyer area outside Hall 4 for those attending the Annual Dinner.

Annual Dinner

**Monday 18th June 2018, Hall 4, ICC Birmingham
7.30pm for 8pm**

The ABS Annual Dinner will be held in Hall 4 at the ICC Birmingham on Monday 18th June 2018 at 7.30pm for 8pm. Attendees must have bought a ticket in advance of the event. The dress code is lounge suits.

Delegates requiring a taxi at the end of the dinner will find a taxi rank at the front of the Hyatt Hotel next door to the ICC.

Asking questions in Hall 1

Delegates wishing to ask a question in the main auditorium (Hall 1) can do so via the internet. Please go to: <https://www.sli.do> or type Slido into a search engine. Then enter the event code #P865 and you will be able to ask a question of the panel.

Alternatively use: <https://app2.sli.do/event/zgr5r3jd/ask> which will take you directly to our event page.



CPD

The Association of Surgeons of Great Britain and Ireland have awarded 6.5 CPD Points for Monday 18th June 2018 and 5.5 Points for Tuesday 19th June 2018.

A CPD certificate has been issued to all delegates with their name badge. Please ensure that you retain this certificate as duplicates cannot be provided.



You can follow the ABS on Twitter @ABSGBI. Please tweet during the ABS Conference using the hashtag #ABSConf18 to be included in the Twitter Feed.




Breast cancer is a challenge best faced together

Come and visit us at
hall 3, booth 18

Endomag®, Sentimag®, Magseed® and Sirona® are registered European Community Trademarks of Endomagatics Ltd. - www.endomag.com



Sentimag® Magseed®



OSNA® RD-210

www.sysmex.co.uk/oncology



Monday 14th January 2019, QEII Centre, London

Genetic testing in 2019 and the management of high risk patients

The ABS will be holding its 5th Multidisciplinary Meeting in January 2019.

CONFIRMED SPEAKERS INCLUDE:

**BRCA prevalence, lifetime risks and implications
of genetic testing**

Prof Gareth Evans

Panel testing

Dr Marc Tischkowitz

**Outcome of genetic procurement exercise and
the National Genetic Test Directory**

Dr Angela George

**Screening high risk patients and risk adaptive
screening**

Prof Fiona Gilbert

**Non mutation high risk patients / PROCAS
programme**

Prof Gareth Evans

**Indications and pathways for risk reducing
surgery**

Mr Ashu Gandhi

Chemoprevention

Dr Sacha Howell

Engage Study

Dr Samuel Smith

Supra-diaphragmatic radiotherapy

Dr Sacha Howell

**POSH study and management of the
contralateral breast**

Prof Diana Eccles

Mainstream genetic testing

Dr Angela George

There will also be a panel debate and case presentations.

*Full programme and registration details will be
available on the website in due course.*

Association of Breast Surgery Trainees Meeting



ABS Trainees Meeting 25th and 26th September 2018 Glasgow Royal Infirmary

Registration is now open for the 2018 ABS Trainees Meeting

ABS Members can register for £80

See the website for further information and to register:
www.associationofbreastsurgery.org.uk

Breast Reconstruction Cadaveric Workshop 27th September 2018 Clinical Anatomy Skills Centre, University of Glasgow

Mr John Scott, Plastic & Reconstructive Surgeon, will be leading the Faculty at the Breast Reconstructive Cadaveric Workshop on the 27th September.

Registration for ABS members is £275 and for non members is £375

Register now at www.associationofbreastsurgery.org.uk



Diary Date



ABS Conference 13th & 14th May 2019 • SEC Glasgow

**This meeting is supported by the
Association of Breast Surgery's sponsors:**





Association of Breast Surgery
at The Royal College of Surgeons
35 – 43 Lincoln's Inn Fields
London WC2A 3PE

T 020 7869 6853/6855
E office@absgbi.org.uk
W www.associationofbreastsurgery.org.uk